UTHR:NGS-United Therapeutics Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 313.29

Change

-24.25 (-7.18)%

Market Cap

USD 5.48B

Volume

0.94M

Analyst Target

USD 144.78
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.52B
ARGX argenx NV ADR

N/A

USD 32.41B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.27B
MRNA Moderna Inc

N/A

USD 28.23B
BGNE BeiGene Ltd

N/A

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 17.44B
RPRX Royalty Pharma Plc

N/A

USD 17.14B
INSM Insmed Inc

N/A

USD 12.93B
SRPT Sarepta Therapeutics Inc

N/A

USD 12.85B

ETFs Containing UTHR

MUUSAS:SW UBS (Irl) Fund Solutions .. 195.50 % 0.00 %

N/A

USD 0.43B
SANE 4.17 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.36 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.91 % 0.00 %

N/A

USD 0.04B
HLTH:AU VanEck Global Healthcare .. 2.64 % 0.00 %

N/A

USD 0.06B
SRHQ Elevation Series Trust - .. 2.36 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 2.09 % 0.00 %

N/A

CAD 0.01B
LABU Direxion Daily S&P Biotec.. 1.95 % 1.14 %

N/A

USD 1.01B
ZUH:CA BMO Equal Weight US Healt.. 1.87 % 0.39 %

N/A

CAD 0.28B
DSMC ETF Series Solutions 1.77 % 0.00 %

N/A

N/A
KRUZ 1.76 % 0.00 %

N/A

N/A
AFMC First Trust Active Factor.. 1.64 % 0.00 %

N/A

USD 0.01B
JMEE JPMorgan Market Expansion.. 1.00 % 0.00 %

N/A

USD 1.36B
THNZ:XETRA L&G Global Thematic ESG E.. 0.85 % 0.00 %

N/A

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.82 % 0.00 %

N/A

N/A
HSMV First Trust Horizon Manag.. 0.69 % 0.00 %

N/A

USD 0.02B
SIXL 6 Meridian Low Beta Equit.. 0.56 % 0.00 %

N/A

USD 0.18B
ETHO Amplify ETF Trust 0.00 % 0.45 %

N/A

USD 0.18B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FNDA Schwab Fundamental U.S. S.. 0.00 % 0.25 %

N/A

USD 8.94B
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

USD 1.30B
GURU Global X Guru Index ETF 0.00 % 0.75 %

N/A

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD 0.10B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

N/A
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD 0.02B
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

N/A

USD 0.24B
FSMD Fidelity Small-Mid Factor 0.00 % 0.00 %

N/A

USD 0.43B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
IUSF:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.22B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.00 %

N/A

USD 0.22B
IWFS:LSE iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.26B
IWSZ:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.26B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
QDVC:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
GLRY Inspire Faithward Mid Cap.. 0.00 % 0.00 %

N/A

USD 0.07B
MIDE DBX ETF Trust - Xtrackers.. 0.00 % 0.00 %

N/A

USD 6.06M
QVMM Invesco Exchange-Traded F.. 0.00 % 0.00 %

N/A

USD 0.32B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 42.48% 80% B- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.48% 80% B- 89% A-
Trailing 12 Months  
Capital Gain 30.08% 75% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.08% 75% C 82% B
Trailing 5 Years  
Capital Gain 276.28% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 276.28% 93% A 93% A
Average Annual (5 Year Horizon)  
Capital Gain 29.24% 79% B- 84% B
Dividend Return 29.24% 79% B- 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.92% 83% B 60% D-
Risk Adjusted Return 94.55% 100% F 96% N/A
Market Capitalization 5.48B 99% N/A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.80 33% 55%
Price/Book Ratio 1.83 63% 50%
Price / Cash Flow Ratio 14.93 4% 20%
Price/Free Cash Flow Ratio 6.24 5% 35%
Management Effectiveness  
Return on Equity 20.08% 98% 90%
Return on Invested Capital 14.58% 89% 84%
Return on Assets 12.25% 99% 97%
Debt to Equity Ratio 5.01% 64% 78%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector